14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
HOLX vs PHG
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
HOLX vs PHG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
HOLX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)
HOLX Overall Winner
6-Pillar Tally: HOLX 3 – 2 PHG (1 Tie)
Matrix Metrics: HOLX 7 – 3 PHG
As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Koninklijke Philips N.V. (PHG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas PHG carries 40.3/100 (SELL) at $28.61 (14.0x Forward P/E, 8.8% operating margin).
HOLX
NASDAQ
Head-to-Head Winner
Hologic Inc
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Market Cap
$16.9B
TTM Revenue
$4.13B
Forward P/E
20.1x
Beta / 30D Vol
0.08β · 3% Vol
Unified Composite Score
64.2 / 100
BUY
Tech 75.0
Fund 61.0
Flow 54.0
Mom 49.2
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 69.0 · SMA20: $75.47 · SMA50: $75.29
PHG
NYSE
Koninklijke Philips N.V.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Market Cap
$28.6B
TTM Revenue
$17.8B
Forward P/E
14.0x
Beta / 30D Vol
0.71β · 38% Vol
Unified Composite Score
40.3 / 100
SELL
Tech 15.0
Fund 39.0
Flow 57.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.0% over 20 days), RSI 51
RSI-14: 51.0 · SMA20: $29.08 · SMA50: $26.59
6-Pillar Scorecard Institutional Category Breakdown (HOLX 3 – 2 PHG)
Columns: Metric · HOLX · PHG
1. Valuation Multiples
PHG
Forward P/E
20.1x
14.0x
Trailing P/E
31.4x
25.4x
PEG Ratio
1.66x
0.90x
EV / Revenue
4.1x
1.9x
2. Growth & Scale
HOLX
Revenue Growth (YoY)
+2.5%
+2.1%
Earnings Growth (YoY)
-9.2%
-85.4%
TTM Revenue (USD)
$4.13B
$17.8B
Market Cap
$16.9B
$28.6B
3. Profitability & Quality
HOLX
Gross Margin
60.4%
46.4%
Operating Margin
23.0%
8.8%
Net Profit Margin
13.2%
5.4%
Return on Equity (ROE)
10.9%
8.6%
4. Balance Sheet & Cash Flow
HOLX
Cash Generation (TTM)
$1.35B EBITDA
$1.82B
Cash Flow Margin
32.7% EBITDA Mgn
10.3%
Net Cash / Leverage
$23.51 Book/Sh · 10.9% ROE
$5.39B Net Debt (0.70x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PHG
Options Structure Phase
UNCLASSIFIED
SURGE
Current IV / %ile
6.3% (3rd %ile)
111.5% (51st %ile)
Put/Call OI Skew
6.20x (Put-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
37.4% of Rev ($1.54B)
37.6% of Rev ($6.68B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Instruments & Supplies Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: HOLX (7) vs PHG (3)
Institutional Metric
HOLX
PHG
Criterion
Row Edge
Market Capitalization
Scale
$16.9B
$28.6B
Larger Scale
PHG
Trailing P/E Ratio
Valuation
31.4x
25.4x
Lower Multiple
PHG
Forward P/E Ratio
Valuation
20.1x
14.0x
Lower Multiple
PHG
Revenue Growth (YoY)
Growth
+2.5%
+2.1%
Higher Growth
HOLX
Operating Margin (TTM)
Profitability
23.0%
8.8%
Higher Margin
HOLX
Net Profit Margin
Profitability
13.2%
5.4%
Higher Margin
HOLX
Return on Equity (ROE)
Capital Efficiency
10.9%
8.6%
Higher ROE
HOLX
52-Week Range Position
Momentum
100% ($52–$76)
51% ($24–$33)
Stronger Trend
HOLX
Beta / 30D Volatility
Risk Regime
0.08β · 3% Vol
0.71β · 38% Vol
Lower Realized Risk
HOLX
Unified Institutional Score
Composite Signal
64.2 / 100 (BUY)
40.3 / 100 (SELL)
Higher Composite
HOLX
Trailing 12M Revenue (USD)
Operating Scale
$4.13B
$17.8B
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.4%
46.4%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.66x PEG · 4.1x EV/Rev
0.90x PEG · 1.9x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.35B EBITDA ($23.51 Book/Sh · 10.9% ROE)
$1.82B ($5.39B Net Debt (0.70x D/E))
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
HOLX +8.63 pp
HOLX:
+0.34%
·
PHG:
-8.29%
3M Horizon
HOLX +1.46 pp
HOLX:
+1.94%
·
PHG:
+0.48%
6M Horizon
HOLX +1.96 pp
HOLX:
+2.48%
·
PHG:
+0.52%
1Y Horizon
HOLX +1.96 pp
HOLX:
+2.48%
·
PHG:
+0.52%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HOLX vs PHG. Trailing 12-month operating profitability (HOLX 23.0% vs PHG 8.8%) and valuation multiples (HOLX 20.1x vs PHG 14.0x Forward P/E) are benchmarked directly in Pillar 4 below.
HOLX ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $4.13B
Gross Margin 60.4%
Op. Margin 23.0%
ROE / Fwd P/E 10.9% · 20.1x
PHG ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $17.8B
Gross Margin 46.4%
Op. Margin 8.8%
ROE / Fwd P/E 8.6% · 14.0x
HOLX
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
6.3%
IV Percentile
3rd %ile
Put/Call OI Skew
6.20x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
PHG
SURGE
12d in phase · OBV DISTRIBUTION
Current IV
111.5%
IV Percentile
51st %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
HOLX Moat Profile
Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $16.9B market capitalization and 23.0% operating margin.
OpEx & R&D Reinvestment
37.4% of Rev ($1.54B)
90D Engineering Disclosures
0 Published
PHG Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $28.6B market capitalization and 8.8% operating margin.
OpEx & R&D Reinvestment
37.6% of Rev ($6.68B)
90D Engineering Disclosures
0 Published
Investor FAQ HOLX vs PHG Key Questions & Quantitative Answers
Is HOLX or PHG a better stock to buy right now?
As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Koninklijke Philips N.V. (PHG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas PHG carries 40.3/100 (SELL) at $28.61 (14.0x Forward P/E, 8.8% operating margin). Technically, HOLX sits in a Neutral phase (RSI 69.0, UNCLASSIFIED options structure) and PHG sits in a Markup phase (RSI 51.0, SURGE options structure).
Does HOLX or PHG have stronger revenue and earnings growth?
HOLX leads the Growth & Scale pillar: HOLX posts +2.5% YoY revenue growth and -9.2% YoY earnings growth on $4.13B TTM revenue (60.4% gross margin, 23.0% operating margin), compared with PHG at +2.1% YoY revenue growth and -85.4% YoY earnings growth on $17.8B TTM revenue (46.4% gross margin, 8.8% operating margin). On trailing 12-month operating scale, HOLX generates $4.13B in USD-normalized revenue versus $17.8B for PHG. In operating R&D and SG&A reinvestment, HOLX deploys 37.4% of Rev ($1.54B) (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($6.68B) (0 disclosures) for PHG.
Is HOLX or PHG cheaper on valuation?
PHG screens cheaper on headline valuation multiples. HOLX trades at 20.1x Forward P/E, 31.4x Trailing P/E, 1.66x PEG, and 4.1x EV/Revenue (32.7% EBITDA margin), whereas PHG trades at 14.0x Forward P/E, 25.4x Trailing P/E, 0.90x PEG, and 1.9x EV/Revenue (10.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HOLX (10.9% ROE) versus PHG (8.6% ROE) capital efficiency.
How is options market volatility positioned on HOLX vs PHG?
In options market volatility and institutional positioning, HOLX carries 6.3% implied volatility (3rd %ile, Compressed (<25th %ile)), a 6.20x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 3% Vol realized risk). By comparison, PHG carries 111.5% implied volatility (51st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.71β · 38% Vol realized risk).
Hologic Inc (HOLX) Research Suite
Koninklijke Philips N.V. (PHG) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.